Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
Reply to a. Avan et Al. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(15):1712, 2015 May 20.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Kiermaier A, Swain S
|
|
|
6.
|
Risk of cardiovascular adverse events from trastuzumab (Herceptin()) in elderly persons with breast cancer: a population-based study. MedStar authors:
Year: 2014
Citation: - Breast Cancer Research & Treatment. 144(1):163-70, 2014 Feb.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Barac A, Freedman AN, Fu AZ, Huang CY, Isaacs C, Potosky AL, Tsai HT, Warren JL
|
|
|
7.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
8.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
Year: 2012
Citation: - New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
9.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors:
Year: 2013
Citation: - Oncologist. 18(3):257-64, 2013.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM
|
|
|
10.
|
|
|
|
11.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors:
Year: 2013
Citation: - Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N
|
|
|
12.
|
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. MedStar authors:
Year: 2013
Citation: - Clinical Cancer Research. 19(13):3681-92, 2013 Jul 1.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Bais C, Brauer MJ, Chen D, Cheng JH, Chung AS, Clermont AC, Ferrara N, Haley B, Hegde P, James CD, Jubb A, Jurinka SS, Kaminker JS, Koeppen H, Kolumam G, Modrusan Z, Ozawa T, Phillips H, Scherer SJ, Schmidt M, Singh M, Stephan JP, Swain SM, Tam RN, Wu X, Yang SX, Yao J, Yeh RF, Yue P, Zhuang G
|
|
|
13.
|
|
|
|
14.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
|
15.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
16.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
|
17.
|
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [Review] MedStar authors:
Year: 2014
Citation: - Lancet. 384(9938):164-72, 2014 Jul 12.
Medline publication type:
- Journal Article
- Meta-Analysis
- Research Support, U.S. Gov't, P.H.S.
- Review
All authors: - Baselga J, Bergh J, Blohmer J, Blumenthal G, Bogaerts J, Bonnefoi H, Cameron D, Cortazar P, Costantino JP, Ditsch N, Eidtmann H, Eiermann W, Fasching PA, Gerber B, Geyer CE Jr, Gianni L, Justice R, Loibl S, Mamounas EP, Mehta K, Paik S, Pazdur R, Perou C, Piccart M, Prowell T, Rastogi P, Semiglazov V, Slaets L, Sridhara R, Swain SM, Tang S, Untch M, Valagussa P, von Minckwitz G, Wickerham DL, Wolmark N, Zhang L
|
|
|
18.
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. MedStar authors:
Year: 2014
Citation: - Journal of Rheumatology. 41(2):300-9, 2014 Feb.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Chatham WW, Freimuth WW, Furie RA, Ginzler EM, LBSL02/99 Study Group, McCune WJ, McKay JD, Merrill JT, Petri MA, Stohl W, Wallace DJ, Weinstein A, Zhong ZJ
|
|
|
19.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
|
20.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
|
21.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors:
Year: 2014
Citation: - Annals of Oncology. 25(6):1116-21, 2014 Jun.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM
|
|
|
22.
|
Pertuzumab for the treatment of breast cancer. [Review] MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Year: 2014
Citation: - Cancer Investigation. 32(8):430-8, 2014 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
|
|
|
23.
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - BMC Cancer. 14:307, 2014.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Beattie M, Hurvitz S, Jahanzeb M, Kaufman PA, Lai C, Masaquel A, Mason G, O'Shaughnessy J, Rugo HS, Swain S, Tripathy D, Yoo B
|
|
|
24.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
25.
|
Treatment of HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(20):1964-5, 2015 May 14.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Swain SM
|
|
|
26.
|
|
|
|
27.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
|
28.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA
|
|
|
29.
|
|
|
|
30.
|
|
|
|
31.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
|
|
32.
|
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(11):1493-1501, 2017 Nov
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Baker LH, Bolejack V, Burgess M, Butterfield LH, Crowley J, D'Angelo S, Davis LE, Hu J, Lazar AJ, Maki RG, Movva S, Okuno SH, Patel S, Priebat DA, Reed DR, Reinke D, Riedel RF, Rodriguez-Canales J, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wistuba II
|
|
|
33.
|
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Lynce, Filipa
- Swain, Sandra M
Year: 2017
Citation: - Oncologist. 22(5):518-525, 2017 May
Institution:
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Medline publication type:
All authors: - Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT
|
|
|
34.
|
Advances in Stroke 2017. [Review] MedStar authors:
Year: 2018
Citation: - Stroke. 49(5):e174-e199, 2018 05.
Institution: - MedStar National Rehabilitation Network
Medline publication type:
All authors: - Amin-Hanjani S, Becker KJ, Bennett DA, Bernhardt J, Dichgans M, Ford GA, Goldstein LB, Goyal M, Greenberg SM, Howard G, Keller E, Kidwell CS, Olivot JM, Pantoni L, Pierot L, Planas AM, Reeves M, Saposnik G, Strbian D, Thrift A, Tymianski M, Woo D, Yenari MA, Zorowitz RD
|
|
|
35.
|
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. MedStar authors:
- Alsaadi, Dana
- Charabaty, Aline
- Jennings, Joseph
Year: 2018
Citation: - Journal for Immunotherapy of Cancer. 6(1):142, 2018 Dec 05.
Institution: - MedStar Washington Hospital Center
Department: - Gastroenterology/Hepatology
Medline publication type:
All authors: - Abu-Sbeih H, Ali FS, Alsaadi D, Charabaty A, Gong Z, Jennings J, Luo W, Richards DM, Wang Y
|
|
|
36.
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors:
Year: 2019
Citation: - Journal of Clinical Oncology. 37(7):537-546, 2019 03 01.
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J
|
|
|
37.
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA
|
|
|
38.
|
|
|
|
39.
|
|
|
|
40.
|
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50. MedStar authors:
Year: 2021
Citation: - Journal of Clinical Oncology. 39(21):2339-2349, 2021 07 20.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, Jensen E, Leal TA, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riess JW, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhao B
|
|
|
41.
|
|
|
|
42.
|
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. MedStar authors:
- Alhaj-Moustafa, Muhamad
- Fitzpatrick, Kelly
- Pilla, Ravi
- Vakiti, Anusha
Year: 2019
Citation: - Journal of Oncology Pharmacy Practice. 25(4):1011-1015, 2019 Jun.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department: - Medicine/General Internal Medicine
Medline publication type:
All authors: - Alhaj-Moustafa M, Fitzpatrick KW, Pilla R, Singh D, Vakiti A
|
|
|
43.
|
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study. MedStar authors:
Year: 2021
Citation: - Leukemia & Lymphoma. 62(8):1816-1827, 2021 08.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ahn IE, Desai S, Drinkwater DC, Farooqui MZ, Gaglione EM, Herman SEM, Hughes TE, Lindorfer MA, Lotter J, Maric I, Marti GE, Mo C, Nichols C, Nierman P, Pleyer C, Soto S, Stetler-Stevenson M, Sun C, Superata J, Taylor RP, Tian X, Valdez J, Wake L, Wiestner A, Yuan CM
|
|
|
44.
|
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. MedStar authors:
- Chen, Kevin
- Kim, Chul
- Peravali, Monica
- Rao, Suman
- Veytsman, Irina
Year: 2021
Citation: - Oncologist. 26(8):694-700, 2021 08.
Institution:
- MedStar Franklin Square Medical Center
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department: - Hematology/Oncology Fellowship
Medline publication type:
All authors: - Ahn J, Chen K, Kim C, Liu SV, Peravali M, Rao S, Veytsman I
|
|
|
45.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|
|
|
46.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
|
|
47.
|
Avastin withdrawal symptoms. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Citation: - Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Editorial
- Research Support, Non-U.S. Gov't
|
|
|
48.
|
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. MedStar authors:
Citation: - Lancet Oncology. 14(9):901-8, 2013 Aug.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Blay JY, Chawla S, Choy E, Ferrari S, Grimer R, Henshaw R, Jacobs I, Kroep J, Qian Y, Reichardt P, Rutkowski P, Schuetze S, Seeger L, Skubitz K, Staddon A, Thomas D
|
|
|
49.
|
Pertuzumab: increasing the options. MedStar authors:
- Nunes, Raquel
- Swain, Sandra M
Citation: - Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar.
Institution: - Washington Cancer Institute
Medline publication type:
- Comment
- Journal Article
- Research Support, Non-U.S. Gov't
|
|
|
50.
|
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. MedStar authors: - Swain, Sandra M MedStar Health
Year: 2024
Citation: - Annals of Oncology. 35(7):630-642, 2024 Jul.
Department: - Associate Dean for Research Development
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F, Kummel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortes J
|
